CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE

被引：3
|
作者：
Chia, Y. L. [1 ]
Tummala, R. [2 ]
Mai, T. [3 ,4 ]
Rouse, T.
White, W. [2 ]
Morand, E. F. [5 ]
Furie, R. [6 ]
机构：
[1] AstraZeneca, BioPharmaceut R&D, San Francisco, CA USA
[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[3] Genentech Inc, Clin Pharmacol & Modeling & Simulat, San Francisco, CA USA
[4] AstraZeneca, BioPharmaceut R&D, Gothenburg, Sweden
[5] Monash Univ, Ctr Inflammatory Dis Monash Hlth, Melbourne, Vic, Australia
[6] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0688
引用
收藏
页码：590 / 591
页数：2
相关论文
共 50 条
  • [1] RELATIONSHIP OF ANIFROLUMAB PK WITH EFFICACY AND SAFETY IN PATIENTS WITH SLE
    Chia, Y. L.
    Zhang, J.
    Tummala, R.
    Rouse, T.
    Furie, R.
    Morand, E. F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 587 - 588
  • [2] PK and PD of seratrodast in patients with moderate asthma
    Samara, E
    Granneman, R
    Locke, C
    Dean, R
    Killian, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII81 - PII81
  • [3] ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Merrill, J.
    Furie, R.
    Werth, V.
    Khamashta, M.
    Drappa, J.
    Wang, L.
    Illei, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
  • [4] ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Merrill, J. T.
    Furie, R.
    Werth, V. P.
    Khamashta, M.
    Drappa, J.
    Wang, L.
    Illei, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 293 - 293
  • [5] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Furie, R.
    Merrill, J. T.
    Werth, V. P.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 168 - 168
  • [6] Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
    Furie, Richard
    Merrill, J. T.
    Werth, V. P.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Furie, R.
    Merrill, J.
    Werth, V.
    Khamashta, M.
    Kalunian, K.
    Brohawn, P.
    Illei, G.
    Drappa, J.
    Wang, L.
    Yoo, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S4 - S4
  • [8] EFFECTS OF ANIFROLUMAB ON RENAL DISEASE IN PATIENTS WITH SLE
    Morand, E. F.
    Furie, R.
    Tanaka, Y.
    Takeuchi, T.
    Abreu, G.
    Tummala, R.
    Lindholm, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 592 - 593
  • [9] Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
    Furie, Richard
    Morand, Eric F.
    Askanase, Anca D.
    Vital, Edward M.
    Merrill, Joan T.
    Kalyani, Rubana N.
    Abreu, Gabriel
    Pineda, Lilia
    Tummala, Raj
    LUPUS, 2021, 30 (08) : 1254 - 1263
  • [10] PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
    Bruce, Ian
    Nami, Alireza
    Schwetje, Erik
    Pierson, M. Edward
    Chia, Yen Lin
    Kuruvilla, Denison
    Abreu, Gabriel
    Tummala, Raj
    Lindholm, Catharina
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345